Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (151-160 of 242) with videos related to

Pageof 25
Sort By:
Orphanet Journal of Rare Diseases|May 5, 2019
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective studyAfshin Saffari, Ines Brösse, Adelheid Wiemer-Kruel, et al.
Neuro-Oncology|December 17, 2020
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 studyJonas E Adolph, Gudrun Fleischhack, Ruth Mikasch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomasKarine Jacob, Dongh-Anh Quang-Khuong, David T W Jones, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Cancers|February 15, 2022
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft ModelsCharlotte Gatzweiler, Johannes Ridinger, Sonja Herter, et al.
Acta Neuropathologica|December 2, 2022
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohortsMartin Mynarek, Denise Obrecht, Martin Sill, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
Acta Neuropathologica|July 4, 2018
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceDavid Capper, Damian Stichel, Felix Sahm, et al.
Pageof 25

Showing results (151-160 of 242) with videos related to

Sort By:
Pageof 25
Orphanet Journal of Rare Diseases|May 5, 2019
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective studyAfshin Saffari, Ines Brösse, Adelheid Wiemer-Kruel, et al.
Neuro-Oncology|December 17, 2020
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 studyJonas E Adolph, Gudrun Fleischhack, Ruth Mikasch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomasKarine Jacob, Dongh-Anh Quang-Khuong, David T W Jones, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Cancers|February 15, 2022
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft ModelsCharlotte Gatzweiler, Johannes Ridinger, Sonja Herter, et al.
Acta Neuropathologica|December 2, 2022
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohortsMartin Mynarek, Denise Obrecht, Martin Sill, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
Acta Neuropathologica|July 4, 2018
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceDavid Capper, Damian Stichel, Felix Sahm, et al.
Pageof 25